Selection made based on a new partnership with ArisGlobal and
Epharma Healthcare Technology
Miami, Florida – January 10, 2019 – ArisGlobal, a leading life sciences technology provider, announced that China-based Fosun Pharma has selected LifeSphere Safety MultiVigilance (LSMV) as its global pharmacovigilance system. Fosun will utilize ArisGlobal’s technology to achieve full E2B R3 compliance with greater efficiency and compliance. The selection was made in conjunction with ArisGlobal partner Epharma Healthcare Technology Co., Ltd, a one-stop solution provider for the pharmaceutical research and development industry.
Fosun Pharma and Epharma join a growing list of biopharmaceutical companies and health authorities making the decision to replace current pharmacovigilance systems with ArisGlobal’s LSMV solution suite. Epharma is an official retail partner for ArisGlobal and will help the company promote the product in the Chinese region. LifeSphere Safety MultiVigilance is currently used by more than 200 life sciences companies, including 9 health authorities.
“Advanced technology, such as artificial intelligence and machine learning, are key LSMV capabilities that help us automate repetitive, manual tasks, thus improving efficiency and compliance,” said Fosun Pharma. “By switching to LifeSphere Safety MultiVigilance, our efforts to comply with regulations will be much more efficient.”
“ArisGlobal offers the most innovative safety, clinical, regulatory, and medical affairs solutions in the Chinese market,” said Sankesh Abbhi, President and CEO, ArisGlobal. “Fosun Pharma is just one example how our customers in China can efficiently and inexpensively meet a wide range of requirements for regulatory compliance and patient safety.”
For more on LifeSphere Safety MultiVigilance: https://goo.gl/KNMaVF
About Fosun Pharma
Fosun Pharma is a leading healthcare group in China established in 1994 and is a A+H listed company, covering key sectors of healthcare industry chain. Fosun Pharma currently got 28,848 employees globally supplied 100 million injectable artesunate to international markets and estimated to have cured more than 20 million patients with severe malaria. Fosun Pharma is ranked among the top 5 domestic pharmaceutical companies in China.
About Epharma Healthcare Technology Co., Ltd
Epharma is committed to the promotion of informatization in Chinese pharmaceutical R&D industry through advanced cloud platform technology to provide a series of solutions for the development from research & clinical to industrialization. At present, there are 30 team members responsible for this business. Before the end of 2019, it will integrate the world’s top pharmaceutical research and development system platform, build a comprehensive data management platform, and the team would have more than 250 employees.